STROBE Statement—Checklist of items that should be included in reports of ***case-control studies***

	Item No	Recommendation	Reported on page numbers/lines	Reported on section/paragraph
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 2 Lines 10-11	Abstract, paragraph 2
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2 Lines 1-21	Abstract, paragraphs 1-3
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 2, Lines 17-25	Introduction Paragraph 3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 2, Lines 20-25	Introduction Paragraph 3
Methods				
Study design	4	Present key elements of study design early in the paper	Page 3, Lines 4-11 Page 6, Lines 2-17	Methods Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4, lines 12-14	Methods Paragraph 1
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Page 4, lines 4-13	Methods Paragraph 1
		(*b*) For matched studies, give matching criteria and the number of controls per case	N/A	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 6, Lines 2-19	Methods Paragraph 1
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability	Page 6 Lines 2-19	Methods Paragraph 1

		of assessment methods if there is more than one group		
Bias	9	Describe any efforts to address potential sources of bias	Page 5, Line 28	Methods Paragraph 2
Study size	10	Explain how the study size was arrived at	Page 4 Line 5	Methods Paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 6 Lines 2-19	Methods Paragraph 1
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Page 6 Lines 2-19	Methods Paragraph 1
		(*b*) Describe any methods used to examine subgroups and interactions	Page 6 Lines 2-19	Methods Paragraph 1
		(*c*) Explain how missing data were addressed	Page 6 Lines 18-19	Methods Paragraph 1
		(*d*) If applicable, explain how matching of cases and controls was addressed	N/A	
		(*e*) Describe any sensitivity analyses	N/A	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 8 Lines 20-25	Results Paragraph 2
		(b) Give reasons for non-participation at each stage	N/A	
		(c) Consider use of a flow diagram	N/A	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 8 Lines 21-22	Results Paragraph 2
		(b) Indicate number of participants with missing data for each variable of interest	Page 8 Line 21	Results Paragraph 2
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	Page 8 Lines 20-25	Results Paragraph 2

Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A	
		(*b*) Report category boundaries when continuous variables were categorized	Page 8 Lines 20-25	Results Paragraph 2
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 9 Lines 2-5	Discussion Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 10, Lines 16-22	Discussion Paragraph 4
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 10, Lines 23-27	Discussion Paragraph 5
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 10, Lines 23-27	Discussion Paragraph 5
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A	

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/jss-20-598.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.